Chinese Journal of Pharmacovigilance ›› 2015, Vol. 12 ›› Issue (9): 547-551.
Previous Articles Next Articles
SONG Yang, YOU Xiao-min, ZONG Mao-mao, YANG Yue
Received:
2015-08-12
Revised:
2015-12-07
Online:
2015-09-08
Published:
2015-12-07
CLC Number:
SONG Yang, YOU Xiao-min, ZONG Mao-mao, YANG Yue. Research of How Traditional Chinese Medicine Can Be Registered as OTC Drug in USA[J]. Chinese Journal of Pharmacovigilance, 2015, 12(9): 547-551.
Add to citation manager EndNote|Ris|BibTeX
[1] 郭莹,王敬博,张宛莹,等.中美两国药品分类管理制度比较及启示[J].中国药事,2010,24(6)612-614. [2] 余辉,吴蓬.国外处方药与非处方药制度概况[J].中国药学杂志,1996,31(6):368-371. [3] U.S. Food and Drug Administration. Office of Drug Evaluation Ⅳ:What We Do [EB/OL]. (2014-12-30) [2015-08-02].http://www.fda.gov/About FDA/Centers Offices/Office of Medical Products and Tobacco/ CDER/ ucm106342.htm. [4] U.S. Food and Drug Administration. Nonprescription Drugs Advisory Committee [EB/OL].(2014-05-11)[2015-08-02].http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Non- prescription Drugs Advisory Committee/default.htm. [5] 王建英.美国药品申报与法规管理[M].北京:中国医药科技出版社,2005:357. [6] U.S. Food and Drug Administration Center for Drug Evaluation and Research.Guidance for industry:Time and Extent Applications for Nonprescription Drug Products[EB/OL]. (2011-09)[2015-08- 02]. http://www.fda.gov/downloads/drugs/guidancecomplianceregul-atoryinformation/guidances/ucm078902.pdf. [7] U.S. Government Publishing Office. Labeling for Bronchodilators To Treat Asthma;Cold, Cough,Allergy,Bronchodilator,and Antiasthmatic Drug Products for Over-the-Counter Human Use [EB/OL]. (2011-07-26) [2015-08-02].http://www.gpo.gov/fdsys/pkg/FR-2011-07-26/pdf/2011-18347.pdf. [8] U.S. Food and Drug Administration Center for Drug Evaluation and Research.Guidance for industry:Botanical drug products[EB/OL].(2004-06)[2015-08-02]. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm-070491.pdf. |
[1] | ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913. |
[2] | QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727. |
[3] | LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785. |
[4] | ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789. |
[5] | LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793. |
[6] | LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569. |
[7] | YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281. |
[8] | LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285. |
[9] | ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192. |
[10] | LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42. |
[11] | SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414. |
[12] | ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024. |
[13] | YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028. |
[14] | SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899. |
[15] | WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||